
## Pietro Tiraboschi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3434993/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
2	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	4.9	432
3	The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 2004, 62, 1984-1989.	1.5	403
4	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
5	Cholinergic dysfunction in diseases with Lewy bodies. Neurology, 2000, 54, 407-407.	1.5	316
6	EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain, 2008, 131, 690-705.	3.7	292
7	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	5.8	263
8	What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. Brain, 2006, 129, 729-735.	3.7	235
9	Longâ€ŧerm acetyl‣â€carnitine treatment in Alzheimer's disease. Neurology, 1991, 41, 1726-1726.	1.5	206
10	Impact of <i>APOE</i> genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology, 2004, 62, 1977-1983.	1.5	192
11	Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. Biological Psychiatry, 2008, 64, 850-855.	0.7	164
12	Behavioral and Psychological Effects of Coronavirus Disease-19 Quarantine in Patients With Dementia. Frontiers in Psychiatry, 2020, 11, 578015.	1.3	157
13	Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease. Archives of General Psychiatry, 2002, 59, 946.	13.8	155
14	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	1.5	151
15	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
16	Diagnostic Accuracy of Dementia With Lewy Bodies. Archives of Neurology, 2000, 57, 347.	4.9	127
17	The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology, 2000, 55, 1278-1283.	1.5	113
18	Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	3.6	106

#	Article	IF	CITATIONS
19	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
20	The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey. Frontiers in Aging Neuroscience, 2020, 12, 625781.	1.7	85
21	Rate of Progression and Prognostic Factors in Alzheimer's Disease: A Prospective Study. Journal of the American Geriatrics Society, 1993, 41, 45-49.	1.3	71
22	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimer's Research and Therapy, 2017, 9, 27.	3.0	66
23	Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of NeuroInterventional Surgery, 2010, 2, 74-79.	2.0	65
24	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	1.4	63
25	Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease*. Clinical Pharmacology and Therapeutics, 1996, 60, 218-228.	2.3	60
26	Prevalence of dementia in the oldest old: The Monzino 80â€plus population based study. Alzheimer's and Dementia, 2015, 11, 258.	0.4	56
27	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	3.7	55
28	Alzheimer disease without neocortical neurofibrillary tangles. Neurology, 2004, 62, 1141-1147.	1.5	54
29	Subthalamic deep brain stimulation improves time perception in Parkinson's disease. NeuroReport, 2004, 15, 1071-1073.	0.6	52
30	Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease. Neurobiology of Aging, 2000, 21, 741-746.	1.5	47
31	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	1.5	47
32	Clinicians' ability to diagnose dementia with Lewy bodies is not affected by β-amyloid load. Neurology, 2015, 84, 496-499.	1.5	44
33	Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology. Journal of the Neurological Sciences, 2011, 310, 166-171.	0.3	43
34	<sup>123</sup> lâ€2βâ€carbomethoxyâ€3βâ€(4â€iodophenyl)â€ <i>N</i> â€(3â€fluoropropyl) nortropane singl emission computed tomography and <sup>123</sup> lâ€metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study. Annals of Neurology, 2016, 80, 368-378.	e photon 2.8	42
35	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
36	Comparison of arterial spin labeling registration strategies in the multi enter GENetic frontotemporal dementia initiative (GENFI). Journal of Magnetic Resonance Imaging, 2018, 47, 131-140.	1.9	41

Pietro Tiraboschi

#	Article	IF	CITATIONS
37	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	3.7	41
38	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	1.5	40
39	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	1.7	39
40	E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology, 2000, 54, 403-403.	1.5	38
41	Pergolide effect on cognitive functions in early-mild Parkinson?s disease. Journal of Neural Transmission, 2005, 112, 231-237.	1.4	38
42	Fluctuating cognition and different cognitive and behavioural profiles in Parkinson's disease with dementia: comparison of dementia with Lewy bodies and Alzheimer's disease. Journal of Neurology, 2010, 257, 1004-1011.	1.8	36
43	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
44	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. Neurolmage, 2019, 189, 645-654.	2.1	33
45	Smoking affects the phenotype of Alzheimer disease. Neurology, 2005, 64, 1301-1303.	1.5	30
46	Neurochemical Markers Do Not Correlate With Cognitive Decline in the Lewy Body Variant of Alzheimer Disease. Archives of Neurology, 1999, 56, 1458.	4.9	28
47	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28
48	Ethical issues in end of life treatments for patients with dementia. European Journal of Neurology, 2010, 17, 774-779.	1.7	27
49	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
50	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
51	Apolipoprotein E and Intronic Polymorphism of Presenilin 1 and Alpha-1-Antichymotrypsin in Alzheimer's Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2000, 11, 239-244.	0.7	26
52	Ethical questions in the treatment of subjects with dementia. Part I. Respecting autonomy: awareness, competence and behavioural disorders. Neurological Sciences, 2007, 28, 216-231.	0.9	26
53	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26
54	A Population-based study of dementia in the oldest old: the Monzino 80-plus Study. BMC Neurology, 2011, 11, 54.	0.8	24

#	Article	IF	CITATIONS
55	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
56	Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiology of Aging, 2019, 76, 9-17.	1.5	23
57	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp> : A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
58	Italian consensus recommendations for a biomarkerâ€based aetiological diagnosis in mild cognitive impairment patients. European Journal of Neurology, 2020, 27, 475-483.	1.7	20
59	Keeping People with Dementia or Mild Cognitive Impairment in Employment: A Literature Review on Its Determinants. International Journal of Environmental Research and Public Health, 2020, 17, 842.	1.2	20
60	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	2.8	19
61	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	0.7	18
62	Cognitive impairment in progressive supranuclear palsy-Richardson's syndrome is related to white matter damage. Parkinsonism and Related Disorders, 2016, 31, 65-71.	1.1	17
63	Incidence of dementia in the oldestâ€old and its relationship with age: The Monzino 80â€plus populationâ€based study. Alzheimer's and Dementia, 2020, 16, 472-481.	0.4	17
64	Conjugal Alzheimer's disease: Is there an increased risk in offspring?. Annals of Neurology, 1993, 34, 396-399.	2.8	16
65	Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. Neurobiology of Aging, 2016, 38, 215.e1-215.e12.	1.5	16
66	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	2.1	16
67	Cerebral amyloid angiopathy in a 51-year-old patient with embolization by dura mater extract and surgery for nasopharyngeal angiofibroma at age 17. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 142-143.	1.4	14
68	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	3.0	12
69	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. Neurological Sciences, 2017, 38, 83-91.	0.9	11
70	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	1.2	11
71	Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts. Frontiers in Neurology, 2020, 11, 1021.	1.1	10
72	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. Neurological Sciences, 2015, 36, 751-757.	0.9	9

#	Article	IF	CITATIONS
73	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
74	Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage. Neurological Sciences, 2008, 29, 256-257.	0.9	8
75	Clinical trial design of serious gaming in mild cognitive impairment. Frontiers in Aging Neuroscience, 2015, 7, 26.	1.7	8
76	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	1.4	8
77	Evaluating Voting Competence in Persons with Alzheimer Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	1.1	6
78	Automatic multispectral MRI segmentation of human hippocampal subfields: an evaluation of multicentric test–retest reproducibility. Brain Structure and Function, 2021, 226, 137-150.	1.2	6
79	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.5	5
80	Atypical features and prognosis of Wallenberg syndrome: Longitudinal study. Italian Journal of Neurological Sciences, 1988, 9, 547-550.	0.1	4
81	A case of convexity subarachnoid haemorrhage from intracranial hypotension treated with epidural blood patch. Neurological Sciences, 2012, 33, 715-716.	0.9	4
82	A promising rating scale for prion disease clinical research. Nature Reviews Neurology, 2013, 9, 366-367.	4.9	4
83	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
84	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldt–Jakob Disease. Frontiers in Aging Neuroscience, 2022, 14, 848991.	1.7	4
85	Developments in vertical tube evaporation. Desalination, 1985, 52, 135-143.	4.0	3
86	Absence of rapid eye movement sleep with hypnopompic visual hallucinations: A possible harbinger of dementia with Lewy bodies?. Sleep Medicine, 2013, 14, 377-379.	0.8	3
87	Singleâ€Dose Safety and Pharmacokinetics of a Potential Cognitionâ€Enhancing Compound, CL 275,838, in Healthy Volunteers. Journal of Clinical Pharmacology, 1993, 33, 845-850.	1.0	2
88	Ethical issues concerning research in patients with dementia. Italian Journal of Neurological Sciences, 1996, 17, 371-375.	0.1	2
89	Disclosing the diagnosis to demented patients. Italian Journal of Neurological Sciences, 1997, 18, 25-28.	0.1	2
90	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2

#	Article	IF	CITATIONS
91	Five years experience in VTE industrial operations and their design improvements. Desalination, 1983, 45, 321-328.	4.0	1
92	Stem cells and neurology: cues for ethical reflections. Neurological Sciences, 2004, 25, 108-13.	0.9	1
93	The role of molecular imaging in the frame of the revised dementia with Lewy body criteria. Clinical and Translational Imaging, 2019, 7, 83-98.	1.1	1
94	The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire. Journal of Alzheimer's Disease, 2020, 78, 387-394.	1.2	1
95	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
96	The <scp>CBlâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
97	Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem). Neurological Sciences, 2022, 43, 4221-4229.	0.9	1
98	Ethical considerations regarding overinvestigation in neurology. Italian Journal of Neurological Sciences, 1993, 14, 97-100.	0.1	0
99	Document on the persistent vegetative state by the Società Italiana di Neurologia (SIN) Working Group on Bioethics and Neurology. Italian Journal of Neurological Sciences, 1993, 14, 643-646.	0.1	0
100	Some comments on the Comitato Nazionale per la Bioetica document "Definition and pronouncement of death in man― Italian Journal of Neurological Sciences, 1993, 14, 647-650.	0.1	0
101	Multipleâ€Dose Pharmacokinetics and Safety of a Potential Memoryâ€Enhancing Compound, CL 275,838, in Healthy Male Volunteers. Journal of Clinical Pharmacology, 1994, 34, 748-753.	1.0	0
102	Ethical issues in the care of patients with amyotrophic lateral sclerosis. Italian Journal of Neurological Sciences, 1995, 16, 328-332.	0.1	0
103	What is the best imaging technique in discriminating dementia with Lewy bodies from other dementias?. Geriatrics and Gerontology International, 2017, 17, 857-857.	0.7	0

104 Dementias. , 2015, , 183-195.

0